How Private Equity Firms Can Create Value From Day One
The video outlines how a private‑equity firm embeds a dedicated “hub” team into every transaction, aiming to generate value from day one rather than after the deal closes. During the due‑diligence phase the hub’s value‑creation specialists work side‑by‑side with the deal team to map out levers such as automation, cross‑selling, geographic rollout and merger‑and‑acquisition opportunities. The firm emphasizes that regulatory complexity in sectors like finance or health care is treated as a source of innovation rather than a barrier. Examples cited include leveraging new regulations to spur competition, backing specialist operators that can quickly scale, and using M&A to accelerate market penetration. The speaker notes that automation and cross‑selling can unlock immediate revenue uplift, while expansion into untapped regions fuels longer‑term growth. For investors, this integrated model promises faster value realization and reduced integration risk, while portfolio companies gain a clear roadmap for scaling under regulatory constraints. The approach signals a shift toward proactive, expertise‑driven private‑equity investing.
David Rubenstein, Co-Founder and Chairman of the Carlyle Group: Pursue Something Meaningful
David Rubenstein, co‑founder of Carlyle, sat down with Stanford to discuss how his blue‑collar Baltimore roots, elite education, and a brief stint in politics shaped his view of purpose‑driven business. He emphasizes that a degree from institutions like Stanford or...
Inside Alts: Arctos Partners’ Ian Charles on Investing in Sports
In this Inside Alts interview, Arctos Partners co‑founder Ian Charles explains why private‑equity firms are increasingly targeting premium sports franchises as a distinct asset class. He frames the move as part of a broader industry maturation, where managers must deliver...
Yetter Manufacturing Acquires Martin Till: Partnership Announcement and Future Plans
Yeter Manufacturing, a family‑owned Illinois firm founded 1930, announced it will acquire Martin Till, a specialist planter‑attachment maker founded 1991, with the deal expected to close by the end of March. The acquisition will keep both brands separate; Martin Till will...
Buy-Side M&A Strategy Explained: How Acquisitions Drive Growth
The video outlines a buyside M&A strategy as a catalyst for companies whose organic growth has stalled. It stresses that acquisitions are not exclusive to large corporations; founder‑led and lower‑middle‑market firms increasingly use them to scale quickly, enter new markets,...
How Data Predicts Investment Success Before You Commit
The video explains how a data‑analytics platform helps private‑equity and corporate‑investment teams forecast the likelihood of a deal’s success before committing capital. By mining a proprietary database of past transactions, the service matches a prospective investment against historical analogs that share...
Why Private Equity Secondaries Are Exploding Right Now
The video explains why the private‑equity secondary market is booming, focusing on institutional investors' shifting strategies. As private‑equity funds mature, large investors such as pension plans, university endowments and sovereign wealth funds have built sophisticated portfolio‑management capabilities. They increasingly sell portions...
Here's How a Consultant Builds Framework for an M&A Case Between Apple & Warner Bros #shorts
The video walks through a consultant’s three‑stage framework for evaluating a potential acquisition of Warner Bros. Discovery by Apple, covering pre‑auction assessment, auction dynamics, and post‑auction execution risk. In the pre‑auction phase the analyst splits the analysis into non‑financial and financial components. Non‑financial...
2026 M&A Boom? What Dealmakers Must Know
Brent Baxter, CEO of the Association for Corporate Growth, predicts 2026 will be a "swell" year for middle‑market M&A as deal flow accelerates. Private‑equity firms are extending hold periods from four to six years, creating a backlog of exits and...
How Investors Find Deal Flow in Secondary Markets
The video explains how investors locate deal flow in secondary markets, emphasizing relationship‑driven sourcing. Prospective investors are routinely asked, “How do you find the deals?” and the answer centers on business‑development work that connects with other general partners (GPs) to...
EBITDA Multiple Explained (How to Value Your Business)
The video breaks down the EBITDA multiple, the metric buyers use to price a company based on its annual operating profit. It explains why EBITDA—earnings before interest, taxes, depreciation, and amortization—offers a cleaner, apples‑to‑apples view of cash generation than net...
Where Your Fund Fits in an LP Portfolio (And Why Specialization Isn’t for Everyone)
The discussion centers on how limited partners (LPs) should evaluate where a fund sits within their broader investment portfolio, weighing the appeal of sector‑specialized managers against the need for diversification. It highlights a market bias toward niche strategies while warning...
Founders, Avoiding FOMO & Navigating Public and Private Market Infrastructure
The episode centers on infrastructure secondary markets and how disciplined investors sidestep FOMO‑driven deals while balancing allocations between public and private assets. The host, a Los Angeles‑based multi‑family office leader, explains their broad mandate—from equity and fixed income to tech, venture,...
How Private Equity Firms Manage Complexity Across Diverse Investments
The video explains how private‑equity firms tackle the inherent complexity of holding a portfolio that spans multiple industries. By structuring their organizations around dedicated deal teams, operating partners, and a central hub, they create a repeatable framework that guides each...
MD&M 2026 Keynote: $6.1B Advice From Ray Cohen and Tom West!
The MD&M West 2026 keynote, titled “Disrupting the Status Quo: Are We Innovating or Just Iterating?”, brought together veteran deal‑maker Ray Cohen and former J&J executive Tom West to debate what true innovation looks like in medical technology. Cohen warned that...
